The ODYSSEY Outcomes trial: Clinical implications and exploration of the limits of what can be achieved through lipid lowering

- Proprotein convertase subtilisin/kexin type 9 inhibitors reduce risk for major adverse cardiac events.
- There is debate about efficacy in patients with low-density lipoprotein cholesterol <100 mg/dL.
- Longer trials are needed to adequately address this question.